Fabino Enterprises Ltd
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products[1]
- Market Cap ₹ 5.57 Cr.
- Current Price ₹ 26.5
- High / Low ₹ 36.5 / 22.8
- Stock P/E 111
- Book Value ₹ 20.0
- Dividend Yield 0.00 %
- ROCE 1.68 %
- ROE 1.21 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 378 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 9.39 | |
2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 6.19 | 9.31 | |
Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | -0.18 | 0.08 |
OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | -3.00% | 0.85% |
0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.29 | 0.11 | |
Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.08 |
Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 |
Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.08 |
Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | ||
0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.05 | |
EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.24 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 25% |
TTM: | 188% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 19% |
TTM: | 400% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -2% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 | 2.10 |
Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 | 2.10 |
2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | 1.21 | |
5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | 8.28 | |
Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.69 |
0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | 0.24 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | 13.40 | |
Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.69 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
0.18 | 2.44 | -0.45 | -1.90 | -0.68 | -0.46 | |
-0.01 | 0.00 | -0.10 | -0.05 | -0.01 | -0.18 | |
-0.18 | -2.37 | 0.45 | 2.47 | 0.34 | 0.43 | |
Net Cash Flow | 0.00 | 0.07 | -0.10 | 0.52 | -0.35 | -0.22 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 |
Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 83.99 |
Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 279.12 |
Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 182.62 |
Working Capital Days | 334.58 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 |
ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
- Closure of Trading Window 21 Mar
-
Announcement under Regulation 30 (LODR)-Resignation of Director
17 Mar - Resignation of Jitender Kumar as Executive Director.
-
Announcement under Regulation 30 (LODR)-Change in Management
17 Mar - Appointment of Mr. Nitin Mehra as Executive Director.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On March 17, 2025
17 Mar - Appointment of Mr. Nitin Mehra and resignation of Mr. Jitender Kumar.
Business Overview:[1][2]
a) FEL is an ISO 9001:2015 pharmaceutical company located near the Delhi NCR region. It offers a wide range of allopathic and herbal products.
b) Company markets pharmaceutical formulation for domestic market and sells through own distribution network and sales force under
their own brand name
c) It gets Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labelling etc.
d) Company exports wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which it also markets